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Purpose: Approval of eribulin for metastatic breast cancer was based on data primarily from Western
patients, and there is a paucity of data on the effectiveness and safety of eribulin for Asian patients. To
determine the effectiveness and safety of eribulin in Korean women with breast cancer in a real-world
setting, we conducted a nationwide, multicenter, retrospective study.
Methods: Patients with locally advanced or metastatic breast cancer who were treated with eribulin in
14 centers throughout Korea were included in this study. Eribulin was generally administered at a dose of
1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate) by intravenous infusion for 2e5 min, or as a
diluted solution, on Days 1 and 8 of every 21-day cycle. The primary endpoint was progression-free
survival (PFS) rate at 6 months. Secondary endpoints included median PFS, overall survival (OS), time-
to-treatment failure (TTF), tumor response rate, and incidence of hematologic treatment-emergent
adverse events (TEAEs).
Results: The safety and full analysis populations included 398 and 360 (38 had no efficacy data) patients,
respectively. The PFS rate at 6 months was 37.8%. Median PFS, OS, and TTF were 134, 631, and 120 days,
respectively. Objective response rate, clinical benefit rate, and disease control rate were 18.1%, 50.6%, and
49.4%, respectively. Hematologic TEAEs were reported in 65.1% of patients; neutropenia (56.8%) and
anemia (11.3%) were most common.
Conclusion: Real-world effectiveness and safety of eribulin in Korean breast cancer patients were
consistent with previous reports; no new safety concerns were identified.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).tal, Yonsei University College
, South Korea.
r Ltd. This is an open access article1. Introduction
Breast cancer is the most commonly diagnosed cancer and a
leading cause of death among females worldwide; there were anunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
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SAF safety analysis set
SD stable disease
TEAE treatment-emergent adverse event
TTF time-to-treatment failure
M.H. Park, S.J. Lee, W.C. Noh et al. The Breast 54 (2020) 121e126estimated 2.1 million newly diagnosed cases of female breast
cancer in 2018 [1]. It is the second most common cancer in Korean
women, with 2456 deaths reported in 2016 [2]. Breast cancer rates
have been on the rise in past decades, particularly in areas that have
historically lower incidences, such as Asia [3]. Since 1999, there has
been a trend of increased incidence of breast cancer in Korea [2].
The current 5-year survival rate for patients presenting with met-
astatic breast cancer is 26% [4].
Eribulin mesylate (hereafter referred to as eribulin) is a unique
non-taxane inhibitor of microtubule growth that disrupts mitotic
spindle formation, induces an irreversible blockade of mitosis, and
leads to cancer cell death by apoptosis [5e10]. It has been shown to
be both efficacious and tolerable as a monotherapy in patients with
advanced and metastatic breast cancer, improving overall survival
(OS) and progression-free survival (PFS) compared with the treat-
ing physicians’ choice of therapy or capecitabine (in certain patient
populations) in phase III clinical studies [11]. These results were
further confirmed in a retrospective study of patients who did not
meet clinical study eligibility requirements [12].
Based on the findings of two phase III studies, EMBRACE [13]
and 301 [14], eribulin was approved in many countries, including
Korea, for the treatment of advanced or metastatic breast cancer in
patients who have been previously treatedwith at least two lines of
chemotherapy, including an anthracycline and a taxane [15,16].
Eribulin was also recently approved in China for the treatment of
locally advanced or metastatic breast cancer, based on the results of
the 304 study [17].
In the EMBRACE study, eribulin treatment significantly
improved PFS and OS compared with the treating physicians’
choice of therapy; of note, fatigue and neutropenia were the most
commonly reported adverse events (AEs) in the eribulin-treated
group [13]. The 301 study showed a non-significant trend to-
wards improvement in OS for patients treated with eribulin
compared with capecitabine, and PFS was similar between the two
groups [14]. However, exploratory subgroup analysis showed an
overall survival benefit with eribulin treatment in patients with
human epidermal growth factor receptor 2 (HER2)-negative, es-
trogen receptor (ER)-negative, and triple-negative disease (ER,
progesterone receptor [PgR], and HER2 negative) [15,18]. Pooled
analysis of EMBRACE and 301 demonstrated a significant
improvement in OS among patients with HER2-negative and triple-
negative disease treated with eribulin [11]. In the recent 304 study,122a multicenter, open-label, randomized phase III trial, which eval-
uated eribulin versus vinorelbine in 530 Chinese patients with
locally recurrent or metastatic breast cancer previously treated
with chemotherapy regimens, including an anthracycline and a
taxane, eribulin demonstrated a statistically significant extension
in PFS (primary endpoint) over vinorelbine according to indepen-
dent imaging review (hazard ratio: 0.80; 95% confidence interval
[CI]: 0.65e0.98; p ¼ 0.036) [17].
While these studies were the basis of approval for eribulin, they
consisted primarily of Western patients and the only clinical study
data of Asian patients were from Japanese metastatic breast cancer
patients and, more recently, one study (304 study) in Chinese pa-
tients [13e21]. To address the shortage of data from Asian patients,
a phase IV clinical study, ESKIMO,was conducted in Korean patients
[22]. This study focused on the safety of eribulin treatment, with
the primary endpoint being frequency and intensity of treatment-
emergent AEs (TEAEs); neutropenia was the most common TEAE
[22]. Other studies have also shown that neutropenia is a common
hematologic AE associated with eribulin use [13,15,19]. Overall,
while the safety data and disease control rates from ESKIMO show
that eribulin is generally safe and well-tolerated in Korean patients
[22], there is still a paucity of efficacy data. Furthermore, the inci-
dence of neutropenia in clinical practice needs further study; it may
be associated with ethnicity as higher rates are reported for Asian
patients [19]. This retrospective study (REMARK) was therefore
conducted to assess the effectiveness and safety of eribulin in
Korean breast cancer patients in a real-world clinical setting.
2. Patients and methods
2.1. Patients
Patients were included in the study if they had confirmed locally
advanced or metastatic breast cancer and had been treated with
eribulin between June 1, 2014 and December 31, 2016. There were
no exclusion criteria. Prior to eribulin administration, all patients
were assumed to have been assessed for peripheral neuropathy and
tested for a complete blood cell count, as indicated in the label
dosing instructions, to check their eligibility for chemotherapy.
2.2. Study design and treatment
This was a retrospective, nationwide, multicenter study con-
ducted across 14 centers throughout Korea between June 1, 2014
and December 31, 2016. Study participants were those who
routinely visited the hospital and were prescribed eribulin by their
treating physician. The data for this study were obtained by
reviewing the past medical records of participating patients. Safety
and effectiveness outcomes from patient medical records were
collected irrespective of the patient’s age, sex, or length of time of
eribulin treatment. Data related to treatment patterns were also
collected.
In general, eribulin was administered at a clinically recom-
mended dose of 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin
mesylate) by intravenous infusion for 2e5 min, or as a diluted so-
lution, on Days 1 and 8 of every 21-day cycle. Dose reductions and
delays were acceptable at the treating physician’s discretion.
This study was conducted in accordance with the principles
outlined in the Declaration of Helsinki, the guidelines of the In-
ternational Conference on Harmonisation of Pharmaceuticals for
Human Use, and the Good Clinical Practice guidelines. The study
protocol was reviewed and approved by the institutional review
board at each participating center. Because this was a retrospective
rather than an interventional study, written informed consent was
not required unless specifically requested by an institutional review
Table 1
Baseline characteristics (safety analysis set).
Total, N ¼ 398
Age (years), mean ± SD 53.0 ± 9.8
Weight (kg), mean ± SD 57.6 ± 10.3
ER/PgR status
ER and/or PgR positive 202 (50.8)
ER and PgR negative 137 (34.4)
HER2 negative 235 (59.0)
HER2 positive 104 (26.1)
Triple negativea 83 (20.9)
Unknown 59 (14.8)






















Prior anthracycline therapy 393 (98.7)
Prior taxane therapy 394 (99.0)
Data are n (%) unless stated otherwise.
ER, estrogen receptor; HER2, human epidermal growth factor receptor-2;
PgR, progesterone receptor; SD, standard deviation.
a ER, PgR, and HER2 negative.
b Patients were included in more than one category if applicable.
M.H. Park, S.J. Lee, W.C. Noh et al. The Breast 54 (2020) 121e126board or regulatory authority. This study was registered on
ClinicalTrials.gov (NCT03437083).
2.3. Effectiveness and safety
The primary effectiveness endpoint was PFS rate at 6 months.
Secondary effectiveness endpoints were median PFS, OS, time-to-
treatment failure (TTF), tumor response rate, and safety. Effective-
ness according to the line of treatment (early [2nd line] vs late
[3rd line]) and receptor status as measured by PFS rate at 6
months, median PFS, OS, TTF, and tumor response rate was also
examined.
The safety endpoint was the incidence of hematologic TEAEs.
TEAE grading was based on the description provided in the clinical
progress notes and the National Cancer Institute Common Termi-
nology for Adverse Events version 4.0 [23]. Adverse drug reactions
were classified by System Organ Class and Preferred Term accord-
ing to MedDRA® version 21.0. Medical Dictionary for Regulatory
Activities terminology is the international medical terminology
developed under the auspices of the International Council for
Harmonisation of Technical Requirements for Pharmaceuticals for
Human Use.
2.4. Statistical analysis
There was no planned sample size as this was a retrospective
study. However, the number of breast cancer patients treated with
eribulin in Korea between June 1, 2014 and December 31, 2016 was
estimated to be approximately 350 based on the internal records of
Eisai Korea Inc. (data not shown). The full analysis set (FAS)
comprised patients with confirmed locally advanced or metastatic
breast cancer who received at least one dose of eribulin and had at
least one efficacy evaluation. The safety analysis set (SAF)
comprised patients with confirmed locally advanced or metastatic
breast cancer who received at least one dose of eribulin and had at
least one safety evaluation.
Effectiveness and safety data were evaluated using descriptive
statistics; demographic and clinical characteristics were summa-
rized using mean, median, or ratio. Categorical variables were
assessed using Chi-square or Fisher’s exact test; continuous vari-
ables were assessed using t-test orWilcoxon rank-sum test. PFS, OS,
and TTF were assessed using the KaplaneMeier method and log-
rank tests. All statistical analyses were performed using SAS soft-
ware (version 9.4, SAS Institute, Cary, NC).
31. Results
3.1. Patients and treatment
Medical records data from 398 female patients were collected
and included in the SAF. Of these, 360 patients were included in the
FAS; the remaining 38 patients were excluded because they did not
have effectiveness data.
The baseline characteristics of patients in the SAF are shown in
Table 1. The mean age ± standard deviation was 53.0 ± 9.8 years,
the median (range) number of previous chemotherapy regimens
for advanced breast cancer was 2 (0e11), and median (range)
number of cycles of eribulin administered was 5 (1e34). The mean
tumor size at the initial breast cancer diagnosis was 3.7 ± 2.6 cm,
the mean number of nodes was 5.3 ± 7.2, and 21.0% (81/385) of
patients had metastatic disease on presentation. Including patients
with unknown receptor status, 50.8% (202/398) were either ER and/
or PgR positive, 34.4% (137/398) were ER and PgR negative, 26.1%
(104/398) were HER2 positive, and 20.9% (83/398) were triple
negative.123The treatment pattern of eribulin in the real-world clinical
setting is shown in Table 2. The FAS had a mean (standard devia-
tion, range) of 6.6 (4.9, 1e34) treatment cycles, a mean (standard
deviation) relative dose intensity of 86.7% (13.8), and 53 (14.8%)
patients had a dose reduction. The mean (standard deviation)
duration of treatment was 139.0 (108.3) days and the median
duration of responsewas 149 days (95% CI: 95.0,194.0). The reasons
for dose change, dose delay, and dose discontinuation were
confirmed for 359 patients and included (n, %): AEs meeting dose
reduction/delay criteria (126, 35.1%), AEs not meeting dose reduc-
tion/delay criteria (74, 20.6%), progressive disease (PD) (296, 82.5%),
and other reason (177, 49.3%).
3.2. Efficacy and safety
The primary effectiveness endpoint of the PFS rate at 6 months
was 37.8% (136/360) (Table 3). When stratified by early (2nd line)
and late (3rd line) use of eribulin, the PFS rates at 6 months were
53.1% (26/49, 95% CI: 38.3, 67.5) and 35.4% (110/311, 95% CI: 30.1,
41.0), respectively. This difference was statistically significant
(P¼ 0.0176) (Supplementary file 1: Supplementary Table 1). PDwas
reported for 60.3% (217/360) of patients at 6 months, and 1.9% (7/
360) of patients had died (Table 3).
KaplaneMeier plots of PFS, OS, and TTF are shown in Fig. 1aec.
Median PFS, OS, and TTF were 134 (approximately 4.5 months, 95%
CI: 119, 148), 631 (approximately 21 months, 95% CI: 571, 761), and
120 days (approximately 4 months, 95% CI: 98, 133), respectively
(Table 3). Best overall response (n [%]) results showed that 3 (0.8) of
Table 2
Real-world treatment patterns (full analysis set).
Treatment pattern N ¼ 360
Relative dose intensity (%), mean (SD) 86.7 (13.8)
Dose reduction 53 (14.8)
Treatment cycles, mean (SD, range) 6.6 (4.9, 1e34)
Duration of treatment (days), mean (SD) 139.0 (108.3)
Median duration of response (days [95% CI]) 149 (95.0, 194.0)
Reason for dose change, delay, or discontinuation (n ¼ 359)
AEs meeting dose reduction/delay criteria 126 (35.1)
AEs not meeting dose reduction/delay criteria 74 (20.6)
Progressive disease 296 (82.5)
Other 177 (49.3)
Data are shown as n (%) unless otherwise stated.
AE, adverse event; CI, confidence interval; SD, standard deviation.
Table 3
Primary and secondary effectiveness endpoints (full analysis set).
Endpoint N ¼ 360 95% CI
Primary endpoint, n (%)
Progression-free survival rate at 6 months 136 (37.8)
Progressive disease 217 (60.3)
Death 7 (1.9)
Secondary endpoints
Progression-free survival, days (median) 134 119, 148
Overall survival, days (median) 631 571, 761
Time-to-treatment failure, days (median) 120 98, 133
Best overall response, n (%)
Complete response 3 (0.8)
Partial response 62 (17.2)
Stable disease 113 (31.4)
Progressive disease 182 (50.6)
Not evaluable 0 (0.0)
Objective response ratea, n (%) 65 (18.1) 14.2, 22.4
Clinical benefit rate (n ¼ 182)b, n (%) 92 (50.6) 43.1, 58.0
Disease control ratec, n (%) 178 (49.4) 44.2, 54.7
CI, confidence interval.
a Complete response þ partial response.
b Complete responseþ partial responseþ stable disease for at least 6 months. The
number of evaluable patients was 182, which was used as a denominator to
calculate the clinical benefit rate.
c Complete response þ partial response þ stable disease.
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response (PR), 113 (31.4) had stable disease (SD), and 182 (50.6) had
PD (Table 3). The objective response rate (ORR), clinical benefit rate
(CBR), and disease control rate (DCR) were 18.1% (65/360; 95% CI,
14.2, 22.4), 50.6% (92/182; 95% CI, 43.1, 58.0), and 49.4% (178/360;
95% CI, 44.2, 54.7), respectively (Table 3).
Significant differences were observed for TTF and ORR
(P ¼ 0.0236 and P ¼ 0.0395, respectively) between the early (2nd
line, n¼ 49) and late (3rd line, n¼ 311) eribulin treatment groups
in the FAS; however, the groups showed no significant differences
in PFS, OS, best overall response, CBR, or DCR (Supplementary file 1:
Supplementary Table 1, Supplementary Fig. 1aec). When catego-
rized by the receptor status, patients who were hormone receptor
(HR)þ and HER2 had the longest (days [95% CI]) median PFS (169
[148, 198]), OS (881 [593, 949]), and TTF (156 [123, 176]) compared
with those whowere HER2þ (107 [79, 145], 705 [568, 1152], and 92
[76, 134], respectively) or triple negative (121 [79, 134], 485 [285,
672], and 110 [71, 123], respectively) (Supplementary file 1:
Supplementary Table 2, Supplementary Fig. 2aec). Patients with
HRþ and HER2 receptor status also showed the best PFS rate at 6
months (48.9%, 67/137), ORR (25.6%, 35/137), and CBR (56.6%, 47/
83) compared with those who were HER2þ (34.7% [34/98], 13.3%
[13/98], and 43.5% [20/46], respectively) or triple negative (25.7%
[19/74], 13.5% [10/74], and 41.4% [12/29], respectively) (Supple-
mentary file 1: Supplementary Table 2). However, for DCR, patients124who were triple negative showed the best response (48.7%, 36/74),
followed by those with HRþ and HER2 status (42.6%, 20/47) and
HER2þ status (40.85, 40/98) (Supplementary file 1: Supplementary
Table 2).
Hematologic TEAEs were reported in 65.1% (259/398) of patients
in the SAF and are summarized in Table 4. Of these, neutropenia
(56.8%) and anemia (11.3%) were the most frequently reported
TEAEs.
4. Discussion
Findings from this study showed the effectiveness of eribulin
treatment in Korean patients with advanced or metastatic breast
cancer in a real-world clinical setting. Additionally, the real-world
safety profile of eribulin was in line with the known safety profile
and no new safety concerns were identified.
Overall, the results of our study are comparable with those
previously reported. Median PFS (134 days, approximately 4.5
months) was comparable with that reported for previous clinical
studies (range: approximately 3e5.1 months) [15,16,20,24,25]. We
also report a slightly longer median OS (631 days, approximately 21
months) than previous studies (range: 8.8e15.9 months)
[15,16,20,24,25]. In a recent retrospective real-world study of data
from 16,703 patents with metastatic breast cancer receiving eri-
bulin as 2nd-to 4th-line therapy, OS in the 3rd- and 4th-line cohorts
was significantly improved with eribulin compared with other
chemotherapy (11.27 vs 7.65months, p¼ 0.0001 [3rd line]; 10.91 vs
5.95months, p < 0.0001 [4th line]) [26]. Interestingly, no significant
difference was reported for 2nd-line eribulin treatment compared
with other chemotherapy; in the present study, there was no sig-
nificant difference in effectiveness of eribulin between early (2nd
line) and late (3rd line) eribulin treatment groups with respect to
OS.
As patient characteristics are difficult to control in the real-
world clinical setting, some differences in results may be ex-
pected. The TTF of 120 days (approximately 4 months) in our study
was comparable with that reported in studies of eribulin treatment
in East Asian populations (Taiwan: 3.9 months; Japan: 127 days
[approximately 4 months]) [21,27]. Best overall responses were
similar among our study (CR, 0.8%; PR, 17.2%; SD, 31.4%; PD, 50.6%)
and the studies conducted in Taiwan (CR, 1.8%; PR, 18.8%; SD, 46.3%;
PD, 33.0%) and Japan (Watanabe et al.: CR, 1.3%; PR, 15.2%; SD,
33.5%; PD, 49.2%; Tanaka et al.: CR, 3.4%; PR, 20.7%; SD, 27.6%; PD,
48.3%) [20,21,27].
The overall safety profile reported in the present study is similar
to what is already known for eribulin treatment in patients with
advanced or metastatic breast cancer [13,14,22]. The most common
hematological AE was neutropenia (56.8%), followed by anemia and
leukopenia (11.3% and 9.8%, respectively), all of which have been
previously reported at either similar or higher occurrence rates
[13,14,22]. Neutropenia is strongly associated with eribulin use
[14,15].
This study had several limitations. First, as this was a retro-
spective study, there are several inherent biases that cannot be
controlled compared with a randomized clinical study. Addition-
ally, we were not able to strictly control the baseline characteristics
of the patients, which may have contributed to variations in
effectiveness outcomes between this study and other retrospective
studies. Secondly, we intended to assess the effectiveness of eri-
bulin treatment according to tumor subtype (receptor status and
molecular subtype); however, we were not able to interpret the
data because of the high percentage (18.0%) of tumors with an
unknown subtype. Finally, no control was set as a clinical factor so
there was no guaranteed control of confounding effects; therefore,
the current results should be interpreted carefully.
Fig. 1. KaplaneMeier plots are shown for a) progression-free survival, b) overall survival c) time-to-treatment failure; full analysis set. CI, confidence interval; OS, overall survival;
PD, progressive disease; PFS, progression-free survival; TTF, time-to-treatment failure.
Table 4
Summary of adverse events (safety analysis set).
Type of adverse event N ¼ 398, n (%)
[events]
Treatment-emergent adverse events 259 (65.1)
[1275]
Adverse drug reaction (related to study drug) 256 (64.3)
[1238]
Serious adverse event 42 (10.6) [114]
Serious adverse drug reaction 41 (10.3) [110]
Incidence of hematologic treatment-emergent adverse






Febrile neutropenia 7 (1.8)
Lymphopenia 7 (1.8)









Treatment-emergent adverse events and serious adverse events were coded ac-
cording to the system organ class and preferred terms of MedDRA® version 21.0.
M.H. Park, S.J. Lee, W.C. Noh et al. The Breast 54 (2020) 121e126The results of this study add to the previously published efficacy
and safety data in patients with metastatic breast cancer regardless
of treatment line and provide much needed efficacy and safety data
for Korean patients. Overall, this retrospective study of Korean
patients with advanced or metastatic breast cancer treated with
eribulin demonstrated effectiveness and safety results from the
real-world clinical setting that are consistent with that reported in
previous studies of eribulin in Asian patients and no new safety125concerns were identified. Regarding further work, larger retro-
spective studies in Korean patients may be warranted to determine
possible relationships between the effectiveness of eribulin and
tumor subtype.
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